Cardiovascular Systems, Inc. (CSII) Reaches $22.09 After 7.00% Up Move; Conatus Pharmaceuticals (CNAT)’s Sentiment Is 1.83

February 15, 2018 - By Lawrence Diaz

The stock of Cardiovascular Systems, Inc. (NASDAQ:CSII) is a huge mover today! The stock increased 4.94% or $1.04 during the last trading session, reaching $22.09. About 375,394 shares traded or 32.98% up from the average. Cardiovascular Systems, Inc. (NASDAQ:CSII) has risen 113.78% since February 15, 2017 and is uptrending. It has outperformed by 97.08% the S&P500.The move comes after 7 months positive chart setup for the $733.79M company. It was reported on Feb, 15 by Barchart.com. We have $23.64 PT which if reached, will make NASDAQ:CSII worth $51.37M more.

Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. The company has market cap of $153.63 million. The Company’s product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for patients with portal hypertension; for liver function; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response. It currently has negative earnings.

Among 9 analysts covering Cardiovascular Systems (NASDAQ:CSII), 4 have Buy rating, 2 Sell and 3 Hold. Therefore 44% are positive. Cardiovascular Systems had 25 analyst reports since August 6, 2015 according to SRatingsIntel. Dougherty & Company maintained Cardiovascular Systems, Inc. (NASDAQ:CSII) on Thursday, October 8 with “Buy” rating. The firm earned “Underperform” rating on Thursday, October 8 by Bank of America. The firm has “Hold” rating by William Blair given on Thursday, December 21. The stock of Cardiovascular Systems, Inc. (NASDAQ:CSII) earned “Outperform” rating by Leerink Swann on Monday, August 22. Bank of America downgraded the shares of CSII in report on Wednesday, June 21 to “Underperform” rating. The rating was downgraded by Zacks to “Sell” on Thursday, September 3. The stock of Cardiovascular Systems, Inc. (NASDAQ:CSII) earned “Underperform” rating by Needham on Friday, January 22. The stock of Cardiovascular Systems, Inc. (NASDAQ:CSII) has “Hold” rating given on Monday, August 10 by Zacks. The stock of Cardiovascular Systems, Inc. (NASDAQ:CSII) has “Strong Buy” rating given on Thursday, August 6 by Needham. The stock of Cardiovascular Systems, Inc. (NASDAQ:CSII) earned “Buy” rating by Needham on Friday, April 1.

Cardiovascular Systems, Inc., a medical technology company, develops, makes, and markets devices to treat vascular diseases in the United States. The company has market cap of $733.79 million. The firm offers peripheral arterial disease products, including Diamondback 360 Peripheral Orbital Atherectomy System , Diamondback 360 60cm Peripheral OAS, Diamondback 360 4 French 1.25 Peripheral OAS, Diamondback 360 1.50 Peripheral OAS, Diamondback 360 2.00 Peripheral OAS, and Stealth 360 Peripheral OAS, which are catheter platforms for treating a range of plaque types in leg arteries above and below the knee, including calcified plaque, as well as address various limitations associated with surgical, catheter, and pharmacological treatment alternatives. It currently has negative earnings. It also provides Diamondback 360 Coronary OAS, an atherectomy device for the treatment of calcified coronary arteries.

Investors sentiment decreased to 0.79 in 2017 Q3. Its down 0.18, from 0.97 in 2017Q2. It dived, as 16 investors sold Cardiovascular Systems, Inc. shares while 50 reduced holdings. 10 funds opened positions while 42 raised stakes. 24.82 million shares or 3.05% more from 24.09 million shares in 2017Q2 were reported. Gabelli Funds Ltd Liability Company accumulated 218,500 shares. Bnp Paribas Arbitrage invested in 0% or 4,523 shares. State Of New Jersey Common Pension Fund D stated it has 15,000 shares or 0% of all its holdings. Invesco Limited invested in 0% or 231,131 shares. First Advsrs Ltd Partnership reported 0% in Cardiovascular Systems, Inc. (NASDAQ:CSII). Savings Bank Of America De, a North Carolina-based fund reported 2,010 shares. Royal Natl Bank Of Canada holds 0% or 22,323 shares. Metropolitan Life Ins New York holds 0% or 22,178 shares in its portfolio. Trexquant L P, Connecticut-based fund reported 9,800 shares. Cubist Systematic Strategies Ltd Liability holds 0.01% or 4,661 shares in its portfolio. Illinois-based Ubs Asset Mngmt Americas has invested 0% in Cardiovascular Systems, Inc. (NASDAQ:CSII). Thrivent Fincl For Lutherans accumulated 153,116 shares or 0.02% of the stock. Northern Tru Corp, a Illinois-based fund reported 427,980 shares. Aqr Cap Mgmt Limited Co reported 0% in Cardiovascular Systems, Inc. (NASDAQ:CSII). Dupont Capital Mgmt Corp accumulated 14,670 shares.

The stock increased 0.99% or $0.05 during the last trading session, reaching $5.12. About 122,088 shares traded. Conatus Pharmaceuticals Inc. (CNAT) has risen 140.55% since February 15, 2017 and is uptrending. It has outperformed by 123.85% the S&P500.

Ratings analysis reveals 100% of Conatus Pharma’s analysts are positive. Out of 2 Wall Street analysts rating Conatus Pharma, 2 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $5.0 while the high is $18.0. The stock’s average target of $11.50 is 124.61% above today’s ($5.12) share price. CNAT was included in 2 notes of analysts from November 9, 2016. On Tuesday, December 20 the stock rating was maintained by H.C. Wainwright with “Buy”. The firm has “Buy” rating given on Wednesday, November 9 by Stifel Nicolaus.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>